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Abstract
Background: It has been observed that mice lacking the sulfatase modifying factor (Sumf1) developed an
emphysema-like phenotype. However, it is unknown if SUMF1 may play a role in Chronic Obstructive Pulmonary
Disease (COPD) in humans. The aim was to investigate if the expression and genetic regulation of SUMF1 differs
between smokers with and without COPD.
Methods: SUMF1 mRNA was investigated in sputum cells and whole blood from controls and COPD patients (all
current or former smokers). Expression quantitative trait loci (eQTL) analysis was used to investigate if single
nucleotide polymorphisms (SNPs) in SUMF1 were significantly associated with SUMF1 expression. The association of
SUMF1 SNPs with COPD was examined in a population based cohort, Lifelines. SUMF1 mRNA from sputum cells,
lung tissue, and lung fibroblasts, as well as lung function parameters, were investigated in relation to genotype.
Results: Certain splice variants of SUMF1 showed a relatively high expression in lung tissue compared to many other
tissues. SUMF1 Splice variant 2 and 3 showed lower levels in sputum cells from COPD patients as compared to controls.
Twelve SNPs were found significant by eQTL analysis and overlapped with the array used for genotyping of Lifelines.
We found alterations in mRNA expression in sputum cells and lung fibroblasts associated with SNP rs11915920 (top hit
in eQTL), which validated the results of the lung tissue eQTL analysis. Of the twelve SNPs, two SNPs, rs793391 and
rs308739, were found to be associated with COPD in Lifelines. The SNP rs793391 was also confirmed to be associated
with lung function changes.
Conclusions: We show that SUMF1 expression is affected in COPD patients compared to controls, and that SNPs in
SUMF1 are associated with an increased risk of COPD. Certain COPD-associated SNPs have effects on either SUMF1
gene expression or on lung function. Collectively, this study shows that SUMF1 is associated with an increased risk of
developing COPD.
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modifying factor 1
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Background
In recent years, Chronic Obstructive Pulmonary Disease
(COPD) has risen to the third leading cause of mortality
world-wide [1]. The disease is irreversible and characterized
by chronic inflammation around the bronchi and bron-
chioles leading to fibrosis, tissue destruction, and the deve-
lopment of emphysema. Smoking is the main risk factor for
developing COPD, although other environmental factors
such as air pollution can also trigger the development of
the disease.
Several recent studies have sought to uncover genetic
causes of COPD in order to better understand the disease
and its progression [2–9]. Through genome-wide asso-
ciation studies (GWAS) and whole genome sequencing,
several genes and single nucleotide polymorphisms (SNPs)
have been identified as being associated with COPD [2, 3].
To date, the only known single gene mutation related to
COPD is in SERPINA1, which leads to alpha1-antitrypsin
deficiency [10]. Multiple cohorts have identified other
genes as being associated with COPD susceptibility, but
their role in the pathology of the disease remains to be
identified [2].
In the lung, the extracellular matrix is important for
the proper formation and maintenance of the struc-
ture of the alveoli, highlighting the importance of pro-
teoglycans in lung development [11]. Sulfatases act on
various cellular substrates, including glycosaminogly-
cans (GAGs) on proteoglycans, and all sulfatases in
the cell are regulated by a single protein, sulfatase
modifying factor-1 (SUMF1) [12, 13]. SUMF1 modu-
lates a very specific and unique post-translational
modification in the active site of sulfatases [14–17].
Mutations in SUMF1 lead to a variety of human dis-
eases, including effects in the lungs, where an over-
abundance of sulfated GAGs accumulate [18–20]. To
date, there have been no reports on measured GAGs
in COPD. Recently, it was observed that a Sumf1−/−
mouse developed an emphysema-like phenotype follow-
ing an arrest of alveolarization [21, 22]. It is, however,
unknown if SUMF1 may be involved in the development
of COPD.
The aim of this study was to examine if SUMF1 is
associated with COPD. Primarily we aimed to inves-
tigate the SUMF1 expression in COPD patients. By
using expression quantitative trait loci (eQTL) ana-
lysis, we investigated if SNPs in SUMF1 were asso-
ciated with SUMF1 expression in lung tissue, and
investigated SUMF1 mRNA expression in sputum
cells and lung fibroblasts. Thereafter, we examined
whether there was a genetic association between
SUMF1 and COPD amongst smokers in a population
based cohort, and subsequently investigated advanced
lung physiology from subjects in the context of the
different genotypes.
Methods
A flowchart diagram (Fig. 1) provides an overview of all
the analyses performed in this study investigating the
associations between SUMF1 and COPD.
Patients in the Lund cohort
Forty controls and 82 COPD patients, defined according
to GOLD criteria (forced expiratory volume in 1 second
(FEV1)/forced volume capacity (FVC) <0.7), were in-
cluded in the Lund cohort (Table 1). All subjects were
current smokers or ex-smokers with >15 pack-years, had
normal levels of alpha-1 antitrypsin, and had no history
of asthma, lung cancer, or any other cardiorespiratory
diseases. They did not suffer from any lower respiratory
infections within 3 weeks prior to the visit. They were
asked to refrain from inhaled bronchodilators for 8 h for
short acting beta agonists and short acting muscarinic
antagonists and 48 h for long acting beta agonists and
long acting muscarinic antagonists before the visit. All
study participants performed flow-volume spirometry,
body plethysmography (MasterScreen Body, Erich Jaeger
GmbH), and single breath helium dilution carbon mon-
oxide diffusion (MasterScreen Diffusion, Erich Jaeger
GmbH) after bronchodilation (400 μg salbutamol,
Buventol Easyhaler®). Lung function measurements were
performed according to manufacturer’s instructions and
European Respiratory Society/American Thorax Society
recommendations [23–25]. The reference values used
were established by Crapo et al. [26] (spirometry), and
from Quanjer et al. [27] (Body plethysmography and
carbon monoxide diffusion). All subjects signed written
informed consent and the study was approved by the
Regional Ethics Review Board in Lund.
Sputum induction and processing
Sputum was induced by inhalation of 3% saline for
5 min, and thereafter 4.5% saline for 2x5 min. After each
step, patients were asked to try to expectorate sputum.
Samples were picked for plugs which were incubated
with 4 volumes of cold 0.1% dithiothreitol in phosphate
buffered saline. After 30 min incubation in 4 °C,
additional 4 volumes of phosphate buffered saline were
added, and the sample was filtered (60 μm filters). Cells
were pelleted at 1000 × g for 5 minutes (4 °C) and lysed
for future RNA analysis [28].
Lung fibroblasts from biopsies
A bronchoscopy was performed in 15 COPD patients.
Central lung biopsies were sampled from which fibro-
blasts were isolated as previously published [29].
RNA extraction and qPCR analysis
For examination of RNA from various body tissues, the
Human Total RNA Master Panel II Lot# 1505145A
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(TakaraBio-Clonetech, Saint-Germain-en-Laye, France)
was utilized.
For mRNA analyses, RNA was extracted from whole
blood, sputum cells, and lung fibroblasts. cDNA synthesis
and quantitative real-time PCR (qPCR) was performed as
described previously [29].
qPCR analysis in the Lund cohort
Multiple protein coding splice variants have been identi-
fied for SUMF1, of which the functional role and tissue
specificity remains unknown. We focused on three well-
established splice variants in SUMF1 (Splice variants 1
(full length), 2 (lacking exon 3) and 3 (lacking exon 8);
For primer sequences and NCBI codes see Additional
file 1: Table S1) that were predicted at the time of this
study. All mRNA expressions were normalized against
expression of the reference genes β-Actin and GAPDH
(see Additional file 1: Table S1).
Patient selection in the Lung eQTL dataset
To assess associations between the SNPs and SUMF1
gene expression in lung tissue (i.e., cis-acting expression
(RNA) quantitative trait loci (cis-eQTL) analysis), the
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Fig. 1 Flowchart diagram providing an overview of the analyses of SUMF1 in relation to COPD done in this study
Table 1 Characteristics of the total Lund cohort
Controls
(n = 40)
COPD
(n = 82)
Sex (male/female) 19/21 46/36
Smoking status (current/former) 7/32a 24/58
Age (years) 68 (66–70) 67 (62–69)
Pack-years 26 (21–36)a 37 (27–48)**
BMI (kg/m2) 27 (23–28) 26 (23–29)
FEV1 (%predicted) 94 (90–103) 60 (49–72)
***
FEV1/FVC 0.77 (0.73–0.79) 0.53 (0.44–0.62)
***
RV (%predicted) 117 (102–128) 144 (116–165)***
TLC (%predicted) 106 (99–111) 113 (102–122)*
RV/TLC 0.41 (0.38–0.46) 0.47 (0.42–0.54)***
VA (%predicted) 90 (86–99) 86 (79–94)*
DLCO (%predicted) 76 (69–89) 58 (48–68)
***
DLCO/VA (%predicted) 88 (78–96) 69 (57–82)
***
Pulmonary function data is post inhalation of β2 agonist (400 μg
salbutamol). Data presented as median (interquartile range). Pack years is
defined as the equivalent of smoking 1 pack per day for a year
BMI body mass index, RV residual volume, TLC total lung capacity,
VA alveolar volume, DLCO diffusion lung capacity
*p < 0.05; **p < 0.01 and ***p < 0.001
amissing data from 1 patient. * depicts significantly different from controls
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Lung eQTL consortium was used, including lung tissue
samples obtained from patients at three participating
sites; University of Groningen (GRN), Laval University
(Laval) and University of British Columbia (UBC) [6].
Tissue was obtained from patients that underwent
lung resectional surgery. DNA samples were genotyped
with Illumina Human1M-Duo BeadChip arrays, and
gene expression profiles were obtained using a custom
Affymetrix microarray. Gene expression data is available
on the Gene Expression Omnibus accession number
GSE23546 and platform GPL10379.
Imputed SNP data was available for 1,095 of the 1,111
subjects, covariate data was missing for another 8
subjects. In the current analyses, we included current
and ex-smokers >40 years with ≥5 pack-years. COPD
was defined as an FEV1/FVC ratio <0.7. Non-COPD
control was defined as an FEV1/FVC ≥ 0.7. In case lung
tissue samples were derived from healthy donors, no
data on FEV1 or FEV1/FVC ratio were available. For
FEV1 and FEV1/FVC, pre-bronchodilator values were
used when post-bronchodilator values were not avail-
able. Subjects with other lung diseases such as asthma,
cystic fibrosis or interstitial lung diseases were excluded.
The final dataset included 512 subjects. Patients
provided written informed consent and the study was
approved by the ethics committees of the Institut univer-
sitaire de cardiologie et de pneumologie de Québec and
the UBC-Providence Health Care Research Institute
Ethics Board for Laval and UBC, respectively. The study
protocol was consistent with the Research Code of the
University Medical Center Groningen and Dutch
national ethical and professional guidelines.
First, cohort specific (GRN, Laval and UBC) principal
components (PCs) were calculated based on residuals
from linear regression models on 2-log transformed gene
expression levels (of each probe separately) adjusted for
age, gender and smoking status (never/ever/unknown).
PCs that explained at least one percent of the total vari-
ance were saved and included as covariates in the main
analysis, these were 14 PCs for GRN and Laval, and 16 for
UBC. Second, in each cohort separately, linear regression
analysis was used to test for association between the SNPs
and 2-log transformed gene expression levels. SNPs were
tested in an additive genetic model and the models were
adjusted for disease status, age, gender, smoking status
and the cohort specific number of PCs. Finally, SNP effect
estimates of the three cohorts were meta-analyzed using
fixed effects models with effect estimates weighted by the
inverse of the standard errors.
A cis-eQTL was defined as a SNP that was significantly
associated with expression levels of a probe (gene) within
a 50 Kb distance of that SNP. We focused on SNPs which
overlapped between eQTL imputed database and Cyto
Chip 12, the array used to genotype the Lifelines cohort.
Associations between SUMF1 SNPs and COPD in the
LifeLines cohort
Associations between SUMF1 SNPs and COPD was
performed in a Dutch general-population based cohort,
the LifeLines cohort study [30]. Subjects with complete
genotype and phenotype data (existing data [30]) were
included when having smoked at least 5 pack-years and
if over 50 years of age. COPD was defined as having
FEV1/FVC < 0.7 and FEV1%predicted < 80, based on
Quanjer et al.[24] with pre-bronchodilator spirometry
following European Respiratory Society/American
Thorax Society criteria [24]. Controls were defined as
having FEV1/FVC ≥ 0.7 and FEV1% predicted > 90.
In the Lifelines cohort, genotyping was performed using
IlluminaCytoSNP-12 arrays and SNPs were included that
fulfilled the quality control criteria: genotype call-rate
≥95%, minor allele frequency ≥1%, and Hardy-Weinberg
equilibrium cut-off p-value ≥10−4. Samples with call rates
below 95% were excluded.
SUMF1 genotyping in the Lund cohort
Whole blood was taken from all subjects in the Lund co-
hort and DNA was extracted. All patients were genotyped
for the SUMF1 SNPs identified to be top hits in the eQTL
analysis and Lifelines using Agena iPLEX genotyping.
Genotyping was performed at the Mutation Analysis
Facility at Karolinska University Hospital (Huddinge,
Sweden) using iPLEX® Gold chemistry and MassARRAY®
mass spectrometry system [31] (Agena Bioscience, San
Diego, CA, U.S.A.). Multiplexed assays were designed
using MassARRAY® Assay Design v4.0 Software (Agena
Bioscience). Protocol for allele-specific base extension was
performed according to Agena Bioscience’s recom-
mendation. Analytes were spotted onto a 384-element
SpectroCHIP II array (Agena Bioscience) using Nanodis-
penser RS1000 (Agena Bioscience) and subsequently ana-
lyzed by MALDI-TOF on a MassARRAY® Compact mass
spectrometer (Agena Bioscience). Genotype calls were
manually checked by two persons individually using
MassARRAY® TYPER v4.0 Software (Agena Bioscience).
Statistics
Descriptive statistics are presented as median (interquar-
tile range (IQR)). P < 0.05 was considered significant.
The differences in gene expression in sputum and
blood between controls and COPD patients were ana-
lyzed using the Mann-Whitney U-test using GraphPad
Prism 5 (Graphpad, La Jolla, CA, USA). In the Lund co-
hort the associations between SNPs and gene expression
in sputum and lung fibroblasts as well as in the lung
physiology was tested using the Kruskal-Wallis test
including Dunn’s Multiple Comparison Post Test (using
Graph Pad Prism 5 software). The eQTL-analyses using
the lung eQTL-consortium data are described above.
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The association between SNPs and COPD in the
Dutch cohort was performed using logistic regression
models including the SNP in a co-dominant genetic
model and adjusted for sex, age, and pack years using
SPSS version 22.
Finally, associations between the SNPs (in an additive
model) and lung function parameters were tested using
linear regression adjusted for COPD, smoking status,
and age in the Lund cohort (using SPSS version 22).
Results
Description of the Lund cohort
Table 1 shows the descriptive statistics of the Lund co-
hort. An adequate sputum sample, from which RNA
could be extracted, could be obtained from 38 subjects
(19 controls and 19 COPD patients, Additional file 1:
Table S2) in the Lund cohort. Additional file 1: Table S3
shows the descriptive statistics of the 15 COPD patients
in the Lund cohort that performed a bronchoscopy, and
from which lung fibroblasts were obtained.
SUMF1 expression is altered in COPD patients compared
to controls
We found that SUMF1 mRNA was expressed relatively
high in whole lung tissue (Figs. 2a-d), and specifically,
Splice variant 3 showed the highest expression in lung
tissue compared to all other investigated tissues in the
body (Fig. 2d).
To examine if SUMF1 expression was systemic or lung
specific, sputum cells and whole blood from COPD pa-
tients and controls from the Lund cohort were examined
for differences in SUMF1 expression. In sputum cells
(Figs. 2e-h), all three splice variants examined were detect-
able and showed significantly lower levels in COPD
patients than controls in Splice variant 2 (p = 0.018) and
Splice variant 3 (p = 0.0086). While in contrast, in whole
blood there was no significant difference in total SUMF1
expression between controls and COPD patients (p = 0.39,
Additional file 2: Figure S1), and the three splice variants
were unable to be detected in the majority of individuals.
Lung expression quantitative trait loci (eQTL) analysis and
linkage disequilibrium analysis
We next performed an expression quantitative trait loci
(eQTL) analysis in lung tissue in order to determine
whether the differential gene expression of SUMF1 were
associated with genetic polymorphisms. In the three
large cohorts (Groningen, Laval, and UBC; n = 512)
examined, twelve of the SNPs, that overlapped with the
array used to genotype the Lifelines cohort, showed
significant expression differences (Table 2).
A linkage disequilibrium (LD) analysis (HaploView
4.2) show the associations between the twelve SUMF1
SNPs identified (Fig. 3a).
The top hit SNP from the eQTL analysis, rs11915920
(Fig. 4a) provided a strong eQTLs (Table 2). For further
data presentation in this study, the most significant SNP
associated with gene expression, i.e., rs11915920, is used
for further data presentation in this study.
The SNP rs793391 (Fig. 4b), the most significant SNP
from the Lifelines cohort (see below), was also a signifi-
cant eQTL (Table 2), but to a much smaller extent.
SUMF1 SNPs show differences in SUMF1 expression in the
lung
In the Lund cohort, the SUMF1 mRNA levels, of total
SUMF1 and the different splice variants, were examined
in sputum cells from controls and COPD patients as well
as in lung fibroblasts from COPD patients in relation to
the SUMF1 genotypes of SNPs rs11915920 and rs793391.
Similar trends in SUMF1 mRNA expression were seen
in both sputum cells and fibroblasts with SNP rs11915920
(Fig. 5). Significant differences were observed among the
rs11915920 genotypes, with a higher expression level in
subjects homozygous for the reference allele (C), in
all splice variants in sputum cells (Fig. 5b-d; Splice
variant 1: p = 0.017, Splice variant 2: p = 0.038, Splice
variant 3: p = 0.015). In lung fibroblasts, the expression of
Splice variant 3 was significantly different between the
genotypes (Fig. 5h, p = 0.014). These in vitro findings
validate the eQTL analysis where there were also higher
levels of mRNA expression observed in subjects with the
reference allele (C) of rs11915920 (Fig. 4a). The top candi-
date from our SNP analyses of the Lifelines cohort (see
below), rs793391, did not show any association with
SUMF1 expression in sputum cells or lung fibroblasts
(Additional file 2: Figure S2). rs793391 was a much weaker
candidate than rs11915920 in the eQTL analysis and the
in vitro analysis corroborates these results.
Association between SUMF1 SNPs and COPD
We also investigated the association between the SUMF1
SNPs associated with eQTLs and COPD in the Dutch
cohort, LifeLines (n = 1483, for descriptive statistics see
(Additional file 1: Table S4)). Convincingly, the reference
allele (A) of SNP rs793391 was associated with a higher
risk for COPD in the LifeLines cohort (Table 3). In
addition, the SNP rs308739 was also associated with
COPD. (For allele frequencies, see Table 4). The most
significant SNP from the association between SUMF1
and COPD, rs793391, was chosen to be followed up
pathophysiologically in this study.
SNP in SUMF1 is associated with lung function
When examining advanced lung physiology in subjects
from the Lund Cohort, including controls and COPD
patients, we found that among the rs793391 genotypes
there was an overall difference in FEV1/FVC (p = 0.031),
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FEV1%predicted (p = 0.035), diffusion capacity (DLCO =
lung diffusion capacity for carbon monoxide)%predicted
(p = 0.027) and alveolar volume (VA)%predicted (p =
0.040). Specifically, subjects homozygous for the refer-
ence allele of rs793391 had lower FEV1/FVC and
FEV1%predicted compared to heterozygous subjects
(Fig. 6a and b, respectively). A similar pattern was seen
in DLCO%predicted (Fig. 6c) and VA%predicted among
the different SUMF1 rs793391 genotypes, but not in
DLCO/VA%predicted. Interestingly, even after correction
for COPD, smoking status and age, the association be-
tween rs793391 and DLCO%predicted remained signifi-
cant, while the association between rs793391 and FEV1/
FVC, FEV1%predicted and VA%predicted did not
(Additional file 1: Table S5).
Neither residual volume, total lung capacity, nor air
trapping index (residual volume/total lung capacity)
showed any difference among the different genotypes of
rs793391 (data not shown).
The SNP rs11915920, highly significant in the eQTL
analyses, did not have any significant association with
measured lung function parameters (Additional file 2:
Figure S3), neither had the SNP rs308739.
Discussion
We found that SUMF1 was associated with COPD. Pri-
marily we showed that SUMF1 is differently expressed
in sputum cells from COPD patients and controls. In
addition, eQTL analysis revealed that several SNPs were
significantly associated with SUMF1 expression, with the
top hit being SNP rs11915920. This was further verified
in mRNA from sputum cells and lung fibroblasts, and
the main differences were in SUMF1 Splice variant 3.
We also show that two SNPs in SUMF1, rs793391 and
308739, were associated with increased risk of COPD in
a population based cohort, LifeLines. Finally, we found
that rs793391 was associated with differences in lung
function parameters.
Our study found, that SUMF1 Splice variant 3 was
most highly expressed in whole lung tissue as compared
to other tissues examined in the body and showed the
biggest expression effect in lung fibroblasts. Splice vari-
ant 3 lacks exon 8 in SUMF1 (Fig. 3b) but, currently, no
effects regarding the protein function or structure of this
variant have been reported. Additionally, rs11915920,
the top hit SNP related to SUMF1 expression in lung tis-
sue, is in close proximity to SUMF1 exon 8 (Fig. 3b),
and might affect the splicing of exon 8. Perhaps Splice
variant 3 is an important variant of SUMF1 specifically
in the lungs with a yet unknown function. Future studies
will be needed to investigate this possibility.
The importance of SUMF1 to the development and
maintenance of alveoli was recently discovered in mice
[21, 22]. Although Sumf1 −/− mice have a very short
Table 2 eQTL analysis of SUMF1 SNPs in lung tissue from three large cohorts (Groningen, Laval, and UBC; n = 512)
SNP Ref Var eQTL meta-estimate (B) eQTL meta-standard error (SE) eQTL meta-p-value
rs11915920 C T −0.110 0.009 6.41E-38
rs2819562 C T −0.096 0.009 2.46E-26
rs809437 A G −0.081 0.011 2.41E-14
rs17030493 T C 0.066 0.013 3.64E-07
rs1687863 G A 0.056 0.013 6.97E-06
rs1968930 A C 0.054 0.014 7.84E-05
rs1688411 T G 0.048 0.014 0.0005
rs807785 C T 0.037 0.011 0.0011
rs308739 A C −0.060 0.019 0.0019
rs1688413 C T 0.035 0.012 0.0028
rs17040589 C T −0.050 0.021 0.0199
rs793391 A C 0.022 0.011 0.0400
Presented are SNPs that were significantly associated with expression levels of a probe (gene) within a 50Kb distance of that SNP and overlapped with the array
used to genotype the Lifelines cohort. Bold indicates significant values
Ref reference allele, Var variance allele
(See figure on previous page.)
Fig. 2 SUMF1 expression is altered in COPD patients. A master panel of mRNA from twenty different human tissues was probed for total SUMF1
mRNA expression (a) as well as three individual Splice variants 1 (b), 2 (c) and 3 (d). Total SUMF1 mRNA expression (e) as well as Splice variant 1
(f), 2 (g) and 3 (h) expression were examined in sputum cells from COPD patients and controls in the Lund cohort. * = p < 0.05 and ** = p < 0.01,
A.U. = Arbitrary units, M-W =Mann-Whitney test used
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lifespan, they have provided a wealth of information re-
garding sulfatase activation and function. In these mice,
there was an overabundance of sulfated GAGs resulting
in inactive sulfatases, leading to an arrest in the alveolar-
ization process and an emphysema-like phenotype [22].
This emphysema-like phenotype was one of our first
hints that perhaps SUMF1 may play a role in the devel-
opment of COPD, which is hallmarked by the develop-
ment of emphysema. In addition to the emphysema-like
phenotype, many cell and tissue types were found to
have massive GAG accumulation in the Sumf1 −/− mice,
but this has not yet been investigated in COPD.
We show that DLCO%predicted is independently af-
fected by the rs793391, since it is not driven by the dis-
ease or smoking status, which is the case for FEV1/FVC
and FEV1%predicted (Additional file 1: Table S5). Our
finding that DLCO%predicted is lower in patients with
the reference allele (A) of rs793391 is in accordance with
the Sumf1 −/− mouse showing a deficient alveolar sept-
ation and a subsequent arrest in alveolar formation.
Interestingly, no difference in residual volume, air trap-
ping index (residual volume/total lung capacity), or
DLCO%predicted corrected for alveolar volume (DLCO/
VA%predicted) was observed between the SUMF1
B
UTR 5´3´
rs793391rs11915920
rs2819562
56 4 3 2 19 8 7
UTR 5´3´ 56 4 2 19 8 7
UTR 5´3´ 56 4 3 2 19 7
Splice
variant 1
Splice
variant 2
Splice
variant 3
rs308739
rs17030493
rs809437
rs1687863
rs1688411
rs1688413
rs1968930
rs807785
rs17040589
A
Fig. 3 Linkage Disequilibrium analysis of SUMF1 SNPs. An LD plot (a) shows the 12 SUMF1 SNPs overlapping between the eQTL analysis and the
array used to genotype the Lifelines cohort. A schematic picture (b) showing localization of the 12 SNPs on the SUMF1 mRNA, and the different
splice variants. Boxes showing exon 1–9, UTR = untranslated region
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A 
B 
AA(228)    AC(231)     CC(53) AA(64)     AC(55)      CC(8) 
AA(104)    AC(106)    CC(34) AA(60)     AC(70)    CC(11) 
Fig. 4 eQTL analysis of SUMF1 SNPs. Each set of box plots represents the three different cohorts, combined (ALL) as well as separately
(GRN = Groningen, Laval = Laval University and UBC = University of British Columbia), and the corrected expression differences seen
between the different SNP genotypes. a represents the SNP rs11915920 and b represents the SNP rs793391. Genotype is presented with
the reference/reference genotype to the left
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Fig. 5 (See legend on next page.)
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genotypes. These findings are also in agreement with the
Sumf1 −/− mouse, suggesting a developmental perturb-
ation of distal alveolar septation rather than a destructive
process. Future studies will be performed in order to
focus on extensive lung physiology in larger cohorts to
determine if the clinical phenotype related to SUMF1
SNPs holds true.
In lung function data, the subjects with homozygous
reference genotype of rs793391 (AA) showed impaired
lung physiology compared to the respective heterozy-
gous genotype. The heterozygous genotype thereby ap-
pears to be protective in association with COPD.
However, there was no significant differences between
the homozygous reference and variance genotypes (AA
versus CC in rs793391), which might be due to the low
number of patients in the Lund cohort that had the
homozygous variance genotype. Unfortunately, only
flow-volume spirometry was performed in the Lifelines
cohort, so we were not able to verify the differences in
DLCO%predicted observed in patients with various
rs793391 genotypes in the Lund cohort. Future studies
will be needed to determine if this potentially protective
genotype holds true for other populations.
A recent GWAS identified genetic variants associ-
ated with total lung capacity in COPD [4]. Among
several SNPs that were identified in patients with
prominent emphysema, one was in SUMF1, however,
it was not studied futher. This GWAS identified SNP
was neither present in our analysis platforms, nor was
it found to be in LD with either of SNPs described in
our study.
To our knowledge this is the first study to genetically
focus on SUMF1 in the context of COPD. Our results
indicate that the different SUMF1 SNPs may be respon-
sible for different factors in the development of the dis-
ease. We showed that several SNPs were associated with
SUMF1 expression, however, on a functional level the
molecular mechanism and their relationship to COPD
remains undiscovered. Alternatively, as all of the SUMF1
SNPs from this study were found to be in introns or un-
translated regions (none are found in translated exons),
there is the possibility that they may act as small RNA
precursors, such as microRNAs. These small RNAs may,
in turn, regulate the expression of SUMF1 or another
unknown gene, but this possibility has yet to be
Table 3 Logistic regression models assessing associations
between SUMF1 SNPs and COPD (additive model) in the
LifeLines cohort
LifeLines cohort
n = 1483
SUMF1 SNP Ref Var OR SE p-value
rs793391 A C 1.42 0.13 0.0066
rs308739 A C 0.40 0.36 0.010
rs807785 C T 0.82 0.13 0.14
rs1688411 T G 0.77 0.18 0.16
rs1968930 A C 0.78 0.19 0.19
rs1687863 G A 0.84 0.15 0.24
rs17030493 T C 0.87 0.17 0.39
rs1688413 C T 0.90 0.14 0.44
rs809437 A G 0.92 0.13 0.55
rs17040589 C T 0.88 0.25 0.62
rs11915920 C T 0.99 0.12 0.90
rs2819562 C T 1.01 0.12 0.96
Shown are SNPs that were significant eQTLs and overlapped with the array
used to genotype the Lifelines cohort. OR = odds ratio, SE = standard error,
p-value is from logistic regression models assessing associations between SNPs
(additive model) and COPD, adjusted for sex, age, and pack years. Smoking
controls were defined as an FEV1/FVC > 0.7 and COPD was defined as an FEV1/
FVC < 0.7. Ref = reference allele. Var = variance allele. Bold indicates
significant values
(See figure on previous page.)
Fig. 5 SUMF1 expression in sputum cells and lung fibroblasts divided by rs11915920 genotype. SUMF1 expression, including the three splice
variants, was examined for SNP rs11915920 in sputum cells (a-d) and lung fibroblasts (e-h) from subjects from the Lund cohort. Both controls and
COPD patients were used for sputum cell analysis and COPD patients for the lung fibroblasts, then divided depending on genotype. Open
symbols = controls, filled symbols = COPD patients. A.U. = Arbitrary units, * = significance at p < 0.05. K-W = Kruskal-Wallis test was used, followed
by Dunn’s multiple comparison post tests (=D). Genotype is presented with the reference/reference genotype to the left
Table 4 Genotype and allele frequencies in the LifeLines cohort
LifeLines cohort
n = 1483
SUMF1 SNP Ref Var Ref/Ref
genotype n (%)
Ref/Var
genotype n (%)
Var/Var
genotype n (%)
MAF
rs793391 A C 669 (45) 644 (43) 170 (12) 0.33
rs308739 A C 6 (0.4) 137 (9) 1340 (90) 0.05
rs807785 C T 122 (8) 587 (40) 774 (52) 0.28
rs1688411 T G 24 (2) 356 (24) 1103 (74) 0.14
rs1968930 A C 22 (2) 339 (23) 1122 (76) 0.13
rs1687863 G A 54 (4) 455 (31) 974 (66) 0.19
rs17030493 T C 35 (2) 395 (27) 1053 (71) 0.16
rs1688413 C T 95 (6) 527 (36) 861 (58) 0.24
rs809437 A G 103 (7) 597 (40) 783 (53) 0.27
rs17040589 C T 9 (1) 164 (11) 1310 (88) 0.06
rs11915920 C T 366 (25) 766 (52) 351 (24) 0.49
rs2819562 C T 293 (20) 775 (52) 415 (28) 0.46
Ref reference allele, Var variance allele, MAF minor allele frequency
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examined. In contrast to rs11915920, which was strongly
associated to SUMF1 expression, rs793391 had a uni-
form impact on lung function. These findings lead us to
believe that the different SNPs may have different roles
in the biology of the disease. SUMF1 is a good candidate
for further study into how the genotype of patients af-
fects the different phenotypes of COPD on a molecular
level. Future studies into downstream effects of SUMF1,
such as sulfatase activity would need to be undertaken
and we can begin to delve deeper into the molecular
mechanisms of the disease and work towards better pos-
sible treatments for those affected.
A limitation of the study is that the different cohorts
have been analysed with platforms investigating different
SNPs, and subsequently only twelve of the significant
SNPs in the lung tissue dataset were found in the
Lifelines cohort. Another limitation is the difference in
rationale for inclusion in the cohorts. The LifeLines co-
hort is a large general-population based study, giving a
high power. However, most COPD patients have only a
mild disease, and the possibility of finding relevant genes
in a multigenetic disease such as COPD might then be
difficult. This might explain why there is a lack of associ-
ation between COPD and several of the different SNPs.
This could also explain why there is a strong relation-
ship between rs11915920 and SUMF1 expression, but no
direct association to COPD in the population based
LifeLines cohort. Maybe a cohort including patients with
more severe COPD would give a significant association
between rs11915920 and COPD. This is suggested from
a subanalysis of the Lund cohort, comparing 24 more se-
vere COPD patients versus the contrasting 24 clearly
healthy controls, showing a significant association to
rs11915920 (data not shown), even though the subject
numbers were low. This hypothesis needs to be further
explored in larger cohorts where more patients with se-
vere COPD are included.
Conclusion
We provide evidence that expression and genetic regula-
tion of SUMF1 differs between smokers with and with-
out COPD. SUMF1 is differentially expressed in sputum
cells from COPD patients and controls. Through exam-
ination of the SUMF1 gene, we found SNPs that
Fig. 6 Lung function in COPD patients and controls divided by SNP
rs793391 genotypes. FEV1/FVC (a), FEV1 (b) and DLCO %predicted (c)
of subjects from the Lund cohort are divided according to the
genotype of rs793391. Open symbols = controls, filled symbols =
COPD patients. * = p < 0.05, ** = p < 0.01. K-W = Kruskal-Wallis test
was used, followed by Dunn’s multiple comparison post tests (=D).
Genotype is presented with the reference/reference genotype to
the left
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significantly affect mRNA levels through the use of an
eQTL analysis from a lung tissue dataset, which was cor-
roborated in vitro by mRNA expression analysis of spu-
tum cells and lung fibroblasts from the Lund cohort. In
addition, some of these SNPs in SUMF1 are associated
with an increased risk of COPD. Furthermore, the differ-
ent SUMF1 SNPs were found to have differential effects
in COPD. Some SNPs, such as rs11915920, had an effect
on SUMF1 mRNA expression in tissue, sputum cells,
and lung fibroblasts, while the SNP rs793391 was signifi-
cantly associated with lung function parameters and
thereby COPD.
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